[Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2].

Oleinik, L A; Madonov, P G; Pykhtina, M B

Oleinik, L A; Madonov, P G; Pykhtina, M B.

Afiliação

Oleinik LA; Research Institute of Clinical and Experimental Lymphology-Branch of Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090 Russia.
Madonov PG; larisaoleynik81@gmail.com.
Pykhtina MB; Research Institute of Clinical and Experimental Lymphology-Branch of Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090 Russia.

Mol Biol (Mosk) ; 57(2): 307-315, 2023.

Article em Ru | MEDLINE | ID: mdl-37000658

RESUMO

This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020-2022. The results of our own studies of pharmacological substances based on recombinant IFN-λ1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-λ as an effective therapeutic agent against SARS-CoV-2.

Assuntos

COVID-19; Interferon lambda; Humanos; Antivirais/uso terapêutico; Antivirais/farmacologia; Interferons/genética; Interferons/uso terapêutico; Interferons/farmacologia; SARS-CoV-2

Palavras-chave

PEG-interferon-λ1; SARS-CoV-2; antiviral activity; recombinant human interferon-λ1

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Interferon lambda Limite: Humans Idioma: Ru Revista: Mol Biol (Mosk) Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google